In one paragraphArticle in The Journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Laura C PlantingaL.C. Plantinga, PhD, J. Fitzpatrick, PhD, Divisions of Rheumatology and Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA; laura.plantinga@ucsf.edu.ORCID 0000-0003-0809-8981 Jessica FitzpatrickL.C. Plantinga, PhD, J. Fitzpatrick, PhD, Divisions of Rheumatology and Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-2686-7628 Mrinalini DeyM. Dey, MBBS, Clinical PhD Fellow, Centre for Rheumatic Diseases, Kings' College London, London, UK.ORCID 0000-0001-6858-4338 Maria Dall'EraM. Dall'Era, PhD, P.P. Katz, PhD, J. Yazdany, MD, Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0001-7439-2316 Charmayne Dunlop-ThomasC. Dunlop-Thomas, MS, MPH, Division of Rheumatology, Department of Medicine, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-5770-1583 Courtney HogeC. Hoge, MSPH, Department of Behavioral, Social, and Health Education Sciences, Emory University, Atlanta, Georgia, USA.ORCID 0000-0001-5500-3709 S Sam LimS.S. Lim, MD, Division of Rheumatology, Department of Medicine, and Department of Epidemiology, Emory University, Atlanta, Georgia, USA.ORCID 0000-0003-2361-0787 Patricia P KatzM. Dall'Era, PhD, P.P. Katz, PhD, J. Yazdany, MD, Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-8146-2519 Jinoos YazdanyM. Dall'Era, PhD, P.P. Katz, PhD, J. Yazdany, MD, Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-3508-4094 Funding
RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2MBurden, correlates, and outcomes of poor cognitive and physical functioning in the lupus populationR01AG061179 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PLANTINGA, LAURA · 2019 to 2024
$1.6MAdvancing Quality and Outcomes Measurement in RheumatologyK24AR074534 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jinoos Yazdany · 2019 to 2026
$1.5MACL HHS U01DP006698ACL HHS U01DP006701NCCDPHP CDC HHS U01 DP006701NIAMS NIH HHS K24 AR074534NIAMS NIH HHS P30 AR070155NIA NIH HHS R01 AG061179
6 · The paper itselfAbstract
objectiveWe leveraged data from 2 population-based systemic lupus erythematosus (SLE) cohorts (Approaches to Positive, Patient-Centered Experiences of Aging With Lupus [APPEAL] and the California Lupus Epidemiology Study [CLUES]) to provide estimates of, and identify factors associated with, perceived and objective physical function (PF) and their discordance.
methodsPerceived PF (Patient-Reported Outcomes Measurement Information System [PROMIS] 12a/10a [APPEAL/CLUES];
resultsAPPEAL (N = 446; 81.4% Black) vs CLUES (N = 173; 41% Asian, 27.7% White, 23.1% Hispanic) participants had lower perceived PF (PROMIS
conclusionOur findings show that perceived and objective PF can vary considerably across SLE populations and patient characteristics. Perceived PF may not always reflect objective PF in SLE populations.
Indexed as
Lupus Erythematosus, SystemicPhysical Functional PerformanceAdultAgedCohort StudiesFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresSeverity of Illness IndexUnited Statesepidemiologyhealthy agingphysical functional performancesystemic lupus erythematosus
Identifiers
PMID41539724
PMCPMC12818546
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390